ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
PROfound: PARP inhibitor olaparib compared with new hormonal agents in advanced ...
Prof Maha Hussain - Northwestern University Feinberg School of Medicine, Chicago...
Analysis of assay used in IMpassion130 to guide treatment of metastatic and adva...
Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Using aspirin for cancer prevention
Prof Ruth Langley - University College London, London, UK
Shaping the future of metastasis - ecancer investigates
Monique Biryiana - ecancer Medical Reporter, Dr Chris Bakal - Dynamical Cell Sys...
Comment: Critical quality attributes of biosimilars
Prof Arnold Vulto - Erasmus University Rotterdam, Rotterdam, Netherlands
Simplifying molecular subtypes of metastatic gastric cancer
Dr Maria Alsina - Vall d'Hebron Instituto de Oncología (VHIO), Barcelona, Spain
VOLFI: FOLFOXIRI and panitumumab in RAS wild-type metastatic colorectal cancer
Dr Dominik Modest - Charité Universitätsmedizin Berlin, Berlin, Germany
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resist...
Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands
Niraparib therapy in patients with newly diagnosed advanced ovarian cancer
Dr Antonio González-Martín - Clínica Universidad de Navarra, Madrid, Spain
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanom...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Dr Jonathan Ledermann - University College Hospital, London, UK
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK